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(57) ABSTRACT 
A system and method for determining the degree of abnor-
mality of a vital sign of a patient by obtaining the clinical 
profile of said patient and determining the statistical differ-
ence between the vital sign of the patient and the vital signs 
of previously evaluated patients having similar clinical 
profiles. The vital signs of previously evaluated patients 
having similar clinical profiles are determined based on 
matching the attributes of the patent's clinical profile to the 
clinical profiles of previously evaluated patients. The statis-
tical difference, and the patent's clinical profile may be 
exported to an electronic medical record system or printed in 
hard copy for inclusion in the patient's medial file. 
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Fig. 2 
1. PATIENT INFORMATION 
1.AGE 
2. RACE drop-down box ( B, W, H, 0, NA, other] 
3.SEX OM OF 
4. HEIGHT ___ in 
5. WEIGHT lb 
2. VITAL SIGNS 3 (spinner boxes) 
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6. Highest RR 7. Highest HR 8. Lowest SBP 9. Lowest Sa02% 10. Temp (F orC) I 
3.SYMPTOMS 
11. FIRST SYMPTOM (drop-down box) 
[Dyspnea, Respiratory distress, Chest pain, Syncope, Seizure, Cough, other ) 
12. SYMPTOM ONSET 0 Sudden 0 Gradual 
13. SYMPTOM DURATION (spinner box, days) 
14. (ifl3. > 2 days) PRIOR VISIT FOR SAME SYMPTOMS 0 Yes 0 No 
4. CURRENT SYMPTOMS AND SIGNS1:J·7 
15. Dyspnea at rest . 0 Yes 0 No 
16. Pleuritic chest pain 0 Yes 0 No 
17. Substernal chest pain 0 Yes 0 No 
18. Unilateral leg or arm swelling 0 Yes 0 No 
·19. Wheezing OYes ONo 
5 SYMPTOMS WITHIN PAST 24 HOURS •;>;3;• 
20. Dyspnea at rest or on exertion OYesONo 
21. Syncope or unexpected seizure OYesONo 
22. Hemoptysis OYesONo 
23. Cough OYesONo 
6. PRIOR LUNG DISEASE'· <NONE or dron-ilowo boxes) 
24. Smoker [stopped,< 10 cigs/day, >10 cigs/day] 
25. Asthma (occasional, monthly attacks, weekly attacks] 
26. COPD (occasional, monthly attacks, weekly attacks] 
27. Other lung disease [Sarcoidosis, asbestosis, lung fibrosis, other] 
7. SURGERY PAST 4 WEEKS?';J (NONE or drop-down box): 
28. [chest, abdominal, orthopedic, spine, bram] 
8. TRAUMA PAST 4 WEEKS? (NONE or drop-down box): 
29. [extremity no immobilization, torso no surgery, CNS no surgery, extremity with immobilization, 
torso requiring surgery, CNS requiring surgery, other] 
9. IMMOBILITY 1 ONE or dro -down box : 
30. [Gener;ilized>48 h, Neurological paralysis, Limb irrunobility, other] 
10. CORONARY ARTERY DISEASE ONE or dro -down box 
31. [None known, Hx CAD without MI, Hx CAD with MI] 
11. CONGESTIVE HEART FAILURE ONE or dro -down box 
32. [LVEFunknown, LVEF>35%, LVEF<35%] 
12. DVT I PE ONE or dro -down box : 
33. (Family history ofDVT or PE, personal history of PE, personal history ofDVT] 
13. MALIGNANCY 1 ONE or dro -down box : 
34. [Treated and inactive, Under treatment, Metastatic, Status unknown] 
14. HEMATOLOGICAL (NONE or drop-down box).: 
35. [Sickle Cell Disease, Sickle -C disease, Factor V mutation, antiphospholipid antibody, other 
thrombophilia] 
15. CONNECTIVE TISSUE DISEASE ONE or dro -down box : 
36. [Lupus, Mixed CT disease, Rheumatoid arthritis, Scleroderma] 
39. [0-7 days, 8-14 days, 15-21days,22-31 days] 
19. CURRENT MEDICATIONS ONE or dro -down boxes : 
40. Warfarin therapy [Noncompliant/INR<l.5, lNR 1.5-2.5, INR>2.5] 
41. Antiplatelet agent [Aspirin, Ticlodipine, other antiplatelet agent] 
4.2. Serotonin reuptake inhibitor 
20. ANXIETY OR OTHER DIAGNOSIS 
43. O History of generalized anxiety disorder, fibromyalgia or panic attacks 
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SYSTEM AND METHOD FOR DETERMINING 
THE DEGREE OF ABNORMALITY OF A 
PATIENT'S VITAL SIGNS 
CROSS REFERENCE TO RELATED 
APPLICATION 
[0001] The present application is a continuation-in-part of 
U.S. patent application Ser. No. 10/267,134, filed Oct. 8, 
2002, which claims priority to U.S. Provisional Application 
Ser. No. 60/371,284, filed Apr. 9, 2002. 
BACKGROUND OF THE INVENTION 
[0002] The present invention generally relates to a system 
and method for evaluating potentially fatal diseases and, 
more particularly, for determining the degree of abnormality 
of one or more vital signs of a patient as compares to 
previously evaluated patients having similar clinical pro-
files. 
DESCRIPTION OF PRIOR ART 
[0003] As technology produces more rapid methods of 
evaluating a patient's risk for contracting a life threatening 
disease, physicians will avail themselves of these technolo-
gies more often, leading to an increase in resource use. 
Owing to new research in imaging and laboratory testing 
over the past five years, protocols for testing patients with 
complaints suggestive of the possibility of a life threatening 
illness in the emergency department have changed substan-
tially at many centers. Three examples are the probability of 
pulmonary embolism (PE) in a patient with chest pain and/or 
shortness of breath, the probability of an acute coronary 
syndrome in a patient with anterior chest pain, and the 
probability of subarachnoid hemorrhage in a patient with a 
headache. For these conditions, emergency physicians are 
becoming more reliant on the use of specific tests and 
diagnostic protocols. For patients with possible PE, physi-
cians can order a D-dimer assay and contrast-enhanced 
computerized tomography (CT). To rule out acute coronary 
syndrome, physicians can invoke a diagnostic protocol that 
includes serial blood chemistry studies and cardiac imaging. 
Finally, to rule out subarachnoid hemorrhage, physicians can 
perform CT scanning followed by lumbar puncture for 
evaluation of the cerbrospinal fluid. The problem with each 
of these examples includes increased time and cost required 
to complete the evaluation, and the possibility of false 
positive testing that can lead to more invasive and poten-
tially more dangerous diagnostic studies and false positive 
diagnoses. The probability of adverse events related to false 
positive testing will increase in proportion to the frequency 
with which patients with a very pretest low probability are 
evaluated for these diseases. 
[0004] Under the pressure of constant overcrowding and 
medical/legal concerns, emergency physicians are ready to 
embrace more rapid and streamlined systems to screen for a 
common and potentially fatal disease. At the same time, 
emergency medicine physicians are taught during residency, 
in the textbooks, and in continuing medical education 
courses, that they must have an unwavering suspicion for the 
potential that every patient with chest pain, shortness of 
breath or headache may have an undiagnosed fatal disease 
process, including acute coronary syndrome, pulmonary 
embolism (PE) and subarachnoid hemorrhage, respectively. 
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As a result, many physicians working in the emergency 
department setting maintain the position that the liberal use 
of screening tests is ethically and medically/legally war-
ranted. 
[0005] As a result of these influences, the frequency of 
objective screening for acute coronary syndromes, PE, and 
subarachnoid hemorrhage has increased sharply, even as 
U.S. emergency departments become even more over-
crowded. In 1998, when the scintillation ventilation-perfu-
sion (VQ) lung scanning was the primary mode of evaluat-
ing PE, 0.39 percent of 96,000 emergency department 
patients underwent a VQ scan. However, in 2000, after 
implementation of CT scanning as the primary method of 
evaluation for PE, CT scans were performed to evaluate for 
PE in 0.69 percent of 102,000 emergency department 
patients. When the PI implemented a "rapid PE rule out" 
system in 2001 (consisting of a decision rule plus a whole-
blood D-dimer plus an alveolar deadspace measurement) the 
rate of screening for PE increased to 1.4% of 108,000 
patients. 
[0006] When physicians in Canada used a scoring system 
and D-dimer as the first step to screen for PE in 946 ED 
patients, the resulting overall probability of PE in the study 
was reduced to 9.5 percent (the lowest yet reported), sug-
gesting very liberal use of testing. Increased screening for 
PE may have negative consequences. A study by Goldstein 
et al, demonstrated that the implementation of a rapid 
D-dimer method to screen for PE produced a net increase in 
the rate of VQ scanning among inpatients. 
[0007] These findings show that as technology produces 
more rapid and easier methods of evaluating for PE, that 
physicians will avail themselves of these technologies more 
often, potentially leading to an increase in resource use. As 
the frequency of screening for PE increases in relatively 
low-risk groups, the number of adverse events related to 
contrast allergy, radiation exposure, and anticoagulant treat-
ment of false positive cases may increase. In other words, 
more rapid tests offer the option of easier evaluation for 
life-threatening illness, but at the risk of being overused in 
an extremely low-risk population. Moreover, as the rate and 
breadth of screening for potentially fatal disease increases in 
relatively low-risk groups, the number of adverse events 
related to contrast allergy, radiation exposure, and treatment 
of false positive cases will also increase. 
[0008] The diagnostic accuracy of the objective tests, such 
as a computed tomography x-ray of the chest, can be defined 
by their likelihood ratio. Likelihood ratios are relatively 
precise variables that are arithmetically defined from sensi-
tivity and specificity data provided by clinical studies. 
Moreover, meta-analysis techniques allow the aggregation 
of the results of many separate studies of one test, to estimate 
a composite likelihood ratio negative for the diagnostic test. 
However, no method exists to calculate a relatively precise 
estimate of the pretest probability of life-threatening dis-
eases. 
[0009] Traditional methods of pretest determination of 
life-threatening diseases involve a particular physician's 
remembered cases, the use of practice databases, planned 
research, and population prevalence. Although remembered 
cases offers an immediate and constantly available method, 
this "gestalt" method lacks reproducibility and is likely to 
vary with training level and can be subject to bias. Practice 
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databases and population prevalence may be helpful for a 
gross estimate for a patient based upon one or two symp-
toms, but current strategies lack the ability to provide 
specialized consideration of age, gender, race, vital sign 
data, and the mosaic of clinical data for any given patient. 
The bulk of published methods for pretest assessment fall 
into the area of planned research. Multiple schemes and 
scoring systems have been devised to estimate the pretest 
probability of life-threatening diseases, including neural 
network systems scoring systems and various criteria based 
upon analysis of clinical factors with Boolean operators. 
These systems are logically designed and are relatively 
straight-forward to use. The drawback to existing methods 
of pretest assessment is that they either underfit or overfit 
individual patients, and only provide ranges of probability 
when, within each range, there exist domains of significantly 
different probabilities. For example, published scoring sys-
tems targeted at PE categorize up to 50 percent of ED 
patients as moderate risk, providing the vague assurance that 
the pretest probability lies between 20 to 60 percent. Pub-
lished scoring systems are also hindered by their assumption 
that each variable functions independently to predict the 
presence or absence of disease of interest, and do not allow 
for a tailor-made clinical profile to be developed for every 
patient. As a result, patients with factors that represent a true 
risk for PE are overlooked in the derivation of the scoring 
system. Additionally, these methods do not factor the com-
plex interdependence of predictors on the probability of the 
disease. 
[0010] In the hospital and clinic setting, physicians and 
risk managers often wish to identify the risk of a particular 
vital sign or clinical feature. This concern also frequently 
arises in the case of civil litigation involving an accusation 
of negligence against a physician. For example, a physician 
may not evaluate a patient for an abnormal vital sign, such 
as a systolic blood pressure (BP) of 92 mm Hg. Under 
certain circumstances, a systolic BP of 92 mm Hg may be 
considered within normal limits. For example, it is fre-
quently believed that females of small habitus will have a 
lower BP than a large male. Accordingly, this may compel 
a physician to ignore as systolic BP of 92 mm Hg and neither 
treat it with fluid infusion or perform any diagnostic studies, 
believing that this is within normal range for that individual. 
[0011] Another example might be if a physician notices a 
pulse oximetry reading of 92% in a 72 year old smoker, the 
physician may believe that this low pulse oximetry reading 
(which is clearing abnormal compared with healthy sub-
jects) is reasonably explained by the patient's age and 
previous lung injury from smoking. If a physician fails to 
take diagnostic action on these abnormalities, and an 
adverse outcome occurs, the issue of whether the physician 
deviated from standard care is often contentious. No existing 
method or system can determine the degree of abnormality 
for these patients compared with "like" or similar subjects, 
as defined by shared clinical characteristics such as age, 
gender, prior disease status. 
[0012] The only conventional method of determining this 
normality is to ask for the experience of previous doctors, 
and to evaluate statistical summary data from published 
research of populations of patients that may share one trait 
with the patient of interest. The disadvantage of this method 
is that it is not possible to take the pages of a published study 
of, for example, 1,000 young women who participated in a 
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birth control study, and parse out only the patients who are 
very similar to the small habitus female (in terms of age, 
gender, and body size), or to examine a study of 1,000 
smokers and select out only males 72 years of age and 
determine their pulse oximeter readings. 
OBJECTS AND ADVANTAGES 
[0013] It is a principle object and advantage of the present 
invention to provide physicians with an accurate method of 
evaluating a patient for the probability of the presence of a 
potentially life-threatening disease. 
[0014] It is a further object and advantage of the present 
invention to provide a method for determining the probabil-
ity of certain outcomes of a potentially life-threatening 
disease, including degree of severity of the disease and the 
probability of death within a defined interval. 
[0015] It is an additional object and advantage of the 
present invention to provide a method of evaluating a patient 
for the probability of the presence of a potentially life-
threatening disease which reduces the likelihood of unnec-
essary diagnostic testing. 
[0016] It is a further object and advantage of the present 
invention to provide physicians with a method for evaluating 
a patient for the probability of the presence of a potentially 
life-threatening disease which incorporates numerous clini-
cal factors that can be obtained by routine clinical interview 
and physical examination. 
[0017] It is an additional object and advantage of the 
present invention to reduce the number of incorrect diag-
noses. 
[0018] It is a further object and advantage of the present 
invention to determine the probability of certain adverse 
outcomes which mandate emergent treatment or interven-
tion. 
[0019] It is an additional object and advantage of the 
present invention to improve the documentation of cases 
histories to reduce or eliminate associated malpractice 
issues. 
[0020] It is also an object and advantage of the present 
invention to provide a system and method for identifying the 
risk associated with a particular vital sign or clinical feature. 
[0021] Other objects and advantages of the present inven-
tion will in part be obvious and in part appear hereinafter. 
SUMMARY OF THE INVENTION 
[0022] In accordance with the foregoing objects and 
advantages, the present invention provides a system and 
method for determining the degree of abnormality of at least 
one vital sign of a patient. First, the clinical profile of the 
patient, including at least one patent attribute and at least one 
patient vital sign of interest to be evaluated is obtained from 
the patient. Next, the clinical profile, including the 
attribute(s) and vital sign(s) are input into a data processing 
unit, such as a computer of personal digital assistant. The 
clinical profile of the patient is compared to the clinical 
profiles of previously evaluated patients to determine and 
retrieve the clinical profiles of previously evaluated patients 
that have attributes corresponding to current patent. The 
statistical difference or differences between the vital sign(s) 
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of the patient and the vital signs of the previously evaluated 
patients may then be calculated. The results, including the 
patient's clinical profile, may be exported to an EMR 
system, printed for inclusion in the patient's medical chart, 
displayed for consideration by a physician, or stored in 
electronic format for future evaluation. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0023] The present invention will be more fully under-
stood and appreciated by reading the following Detailed 
Description in conjunction with the accompanying draw-
ings, in which: 
[0024] FIG. 1 is a flowchart of the method of the present 
invention. 
[0025] FIG. 2 is an example of an electronic data form for 
use with the present invention. 
[0026] FIG. 3 is a flowchart of a hypothetical determina-
tion of pretest probability according to the present invention. 
[0027] FIG. 4 is a flowchart of an additional embodiment 
of the present invention. 
[0028] FIG. 5 is a flowchart of a further embodiment of 
the present invention. 
DETAILED DESCRIPTION 
[0029] Although this description refers to a pulmonary 
embolism (PE) as the primary disease, the method and 
system of the present invention may be used to predict the 
pretest probability of other disorders, including but not 
limited to, acute coronary syndrome and subarachnoid hem-
orrhage. The invention will also be applied to evaluate the 
probability of certain life-threatening diagnoses or other 
clinical outcomes in patients with symptoms or complaints, 
including, anterior chest pain, headache, syncope, symptoms 
consistent with transient ischemic attack, fever, minor head 
injury, shortness of breath, seizure, altered mental status, 
abdominal pain, trauma, dizziness, weakness, high blood 
pressure, and low blood pressure. 
[0030] Referring now to the drawings in which like 
numerals refer to like parts through out, there is seen in FIG. 
1 a flow chart of the method of present invention for 
determining a particular patient's pretest probability 10 for 
PE. Prior to starting the process for determining pretest 
probability 10 for a particular patient, however, it is neces-
sary to create a reference database 20 containing clinical 
data for a sample population previously tested for PE which 
is then stored in reference database 30. 
[0031] The collection of reference data 40 for reference 
database 30 may be performed by a variety of conventional 
methods, such as entering the information from a patient's 
medical history directly into a computer database. Alterna-
tively, the present invention contemplates the use of an 
electronic form 50 programmed as part of an application for 
use, for example, on a personal digital assistance (PDA). 
[0032] As seen in FIG. 2, electronic form 50 contains 
entry lines for a wide variety of information, from patient 
background information to specific clinical data relevant to 
diagnosis of a particular disease, such as a PE in the example 
case. A physician enters the answers to the numbered 
3 
Nov. 16, 2006 
questions on electronic form 50 as they are obtained directly 
from the patient or from the patient's medical records. 
[0033] Electronic form 50 is designed to allow very quick 
and easy input at the bedside. The content and number of 
fields in the form elicit data, which represent the pretest 
parameters that are immediately available at the bedside, 
including results of 12-lead electrocardiography. The pro-
spective parameters that are included have previously been 
demonstrated to be important to the diagnosis and exclusion 
of PE based upon patient samples from emergency depart-
ments in the United States, Canada and Switzerland. 
Because electronic form 50 may be filled out in real-time in 
the PDA, its format allows the rapid entry of the key 
information that is most likely to help distinguish patients 
with PE from those without PE while minimizing the time 
requirement to enter the information. 
[0034] After docking of the PDA containing electronic 
form 50 to a cradle device or other electronic means, newly 
created or updated electronic forms 50 are uploaded to a 
central computer or designated website programmed to 
assimilate and analyze the reference data 60. Electronic form 
50 may alternatively be used to collect data from prospec-
tively studied patients, retrospectively studied patients who 
were previously evaluated for PE, retrospectively studied 
patients with PE who were known to have been evaluated by 
a physician who failed to diagnose PE including patients 
who were the subject of civil litigation. It should be under-
stood that the database can be built from as many sources as 
are required to provide sufficient reference data to establish 
a statistically significant database. 
[0035] It is anticipated that a different database will be 
established to evaluate for the pretest probability of PE, 
acute coronary syndrome, subarachnoid hemorrhage and 
other life-threatening diseases. Separate databases will be 
assimilated to determine the probabilities of certain life-
threatening diseases or outcomes for specific complaints, 
symptoms or signs including, anterior chest pain, headache, 
syncope, neurological symptoms consistent with transient 
brain ischemia, fever, minor head injury, shortness of breath, 
seizure, altered mental status, abdominal pain, trauma, diz-
ziness, weakness, high blood pressure, and low blood pres-
sure. 
[0036] Once an accurate reference database 30 has been 
established, pretest probability 10 can be calculated from a 
personal computer or a personal digital assistant (PDA) 
which can access reference database 30 and which is pro-
grammed to perform a comparison of the patient data 70 to 
reference database 30. As seen in FIG. 1, patient data 62 is 
first obtained from the patient whose pretest probability 10 
is to be determined. The data may comprise the same 
information which was obtained via electronic form 50 and 
used to compile the reference database, or may comprise 
only the most relevant, "cardinal" characteristics indicative 
of PE as determined by assimilating and analyzing the 
reference data 60. For example, multivariate logistic regres-
sion analysis or classification and regression tree analysis 
will be performed on reference database 30 to determine 
which parameters should be included as cardinal data to be 
used to estimate the probability of PE. Cardinal parameters 
may include continuous data, such as body mass index, age, 
gender, and vital signs as well as categorical data, such as 
gender, race, and the presence or absence of other factors. 
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[0037] Once patient data 60 is obtained, it is compared 70 
to the reference database 30 to return matching reference 
patient data, i.e., reference patients with corresponding data 
points stored in reference database 30. Comparison 70 
begins by taking the patient's individual data points, e.g., 
age, pulse rate, respiratory rate, systolic blood pressure, 
pulse oximetry, and temperature, and establishing a clini-
cally relevant interval for each. Clinically relevant intervals 
are a given range for continuous data parameters. For 
example, patient age may be broken into 0-30 years, 31-45 
years, 46-65 years, etc. The number and width of the 
intervals for each relevant parameter will be chosen based 
upon a histogram plot of the frequency (i.e., probability) of 
the disease versus the parameter. The width of the interval 
for each continuous parameter will be set to contain no more 
than 33.3% of the total number of patients in the database 
who are disease positive. The width of the interval will vary 
with the specific parameter, the size of the reference data-
base, and the frequency of the disease in the reference 
database population. A match is determined by searching the 
database to see whether any reference patients in reference 
database 30 have a data point within the interval established 
for that parameter based upon data from the new patient for 
whom the pretest probability is unknown. 
[0038] The cardinal parameters are expected to include, 
but not be limited to, symptoms (e.g., dyspnea, chest pain 
location, syncope, cough with hemoptysis, cough without 
hemoptysis), findings (e.g., unilateral leg swelling and 
wheezing on auscultation of the lungs), and risk factors (e.g., 
prior pulmonary embolism, recent surgery, malignancy, oral 
contraceptive use, pregnancy, and post partum status) and 
alternative processes (e.g., smoking, history of asthma, 
history of COPD, or other chronic lung disease). The patient 
is matched unconditionally to these cardinal parameters. 
[0039] The patient may also be matched to additional data, 
termed "conditional" parameters, also recorded for each 
patient within reference database 30. Conditional parameters 
will have less importance in predicting the pretest probabil-
ity according to the multivariate regression or classification 
and regression tree analysis. Conditional parameters signifi-
cantly reduce the number of patients in the database that 
yield a match. As a result, pretest probability 10 can deter-
mined with and without conditional matches. A large dis-
parity (e.g. >20%) between the pretest probability estimate 
using only cardinal parameters compared with the pretest 
probability obtained by matching of cardinal plus condi-
tional parameters may indicate that the results of the former 
are not reliable. If in addition, the 95% confidence intervals 
for the pretest probability estimate from the cardinal plus 
conditional parameter match is very wide (e.g >30%), the 
results of the pretest probability estimate should be consid-
ered invalid for clinical decision-making. For the estimation 
of the pretest probability of PE, parameters that are likely to 
fall into the conditional category include, but are not limited 
to, duration of symptoms, the first symptom experienced, 
whether the patient has sought medical attention for the 
same complaint recently, body mass index, pregnancy, post-
partum status, the presence or absence of sickle cell disease, 
connective tissue diseases, known coronary artery disease, 
congestive heart failure, family history of clots, estrogen 
replacement therapy, and history of anxiety or fibromyalgia. 
[0040] By returning matching reference patients 72 using 
cardinal and conditional parameters, two pretest probabili-
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ties 80 with successively more exact matching and a 
decreasing number of matches can be determined. Thus, the 
application of method of the present invention will show the 
trade-off between precision of clinical matching and preci-
sion of the point estimate for pretest probability (based upon 
the 95% confidence interval). The first estimate will return 
the largest number of patients, matched for age and vital sign 
intervals, and exactly for cardinal features. The second will 
be all patients in the first group subjected to more exact 
matching for conditional variables. 
[0041] Calculating the pretest probability and confidence 
interval 80 uses the traditional method to compute a 95% 
confidence interval. If x equals the number of subjects 
matched to a new patient and d equals the number of those 
matched subjects previously determined to have the disease 
in question, then the proportion of subjects with the disease 
(p ), and the proportion of subjects without the disease ( q) is 
calculated as follows: 
p~dlx 
q~l-p 
[0042] The standard error [SE(p )] is determined according 
to the formula: 
SElp){square root}~lp*q)/{square root}x 
[0043] The formulas for calculating the upper and lower 
levels of the confidence intervals using a 95th percentile 
critical ratio from the normal distribution (1.96) are deter-
mined, respectively, as follows: 
p+[l.96*SElp)] 
p-[1.96*SElp)] 
[0044] If d is less than 5 or if x-d is less than 5, then the 
"exact" methods as described by Newcomb and Altman, 
Chapter 6, Proportions and Their Differences in Statistics 
with Confidence, 2nd ed. (BMJ, Bristol, UK), hereby incor-
porated by reference, may be used. 
[0045] Alternatively, using modification of the above for-
mulae, other confidence intervals can be selected by the user, 
including a 99% confidence interval or the computation of 
the Bayesian credible interval. Once the pretest probability 
and associated confidence intervals are calculated 80, the 
results are displayed for the treating physician. Additionally, 
the query and results may be stored 110 along with date and 
time stamps to accurately record the entire pretest probabil-
ity 10 process in permanent electronic storage. 
[0046] As seen in FIG. 4, reference database 30 can 
further be configured to return other important outcome data 
for use in calculating probabilities helpful to a physician. 
This data, in conjunction with calculated pretest probability 
90, may be used to calculate post-test probabilities 120, the 
percentage oflike patients who experienced death within 30 
days of diagnosis 140, and the percentage of like patients 
who were ultimately diagnosed with another clinically 
important disease besides the disease under primary consid-
eration 170. 
[0047] For example, the returned results could include the 
number of patients in the matched set who were diagnosed 
with a myocardial infarction as opposed to PE. 
[0048] For the purpose of calculating the post-test prob-
ability 120 of PE, the PDA or electronic device can be 
preprogranimed with published likelihood ratio data 110 for 
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multiple tests, and the clinician can choose the test that he 
or she is considering. These tests include, but are not limited 
to, the D-dimer assay, contrast-enhanced computerized 
tomography angiography of the chest, scintillation ventila-
tion-perfusion lung scanning (broken down into four 
results), echocardiography, normal plain film chest radio-
graph, normal alveolar deadspace measurement, and normal 
arterial oxygen partial pressure. 
[0049] The post-test probability 120 (postP) of a disease is 
calculated by first obtaining the pre-test probability 90 
(PreP) according to the present invention. The likelihood 
ratio negative (LRn) for a negative test result is calculated 
from published sensitivity and specificity data for the 
selected test according to the following formula: 
LRn~(l -sensitivity )/specificity 
[0050] The pre-test odds (PreO) and post-test odds 
(PostO) are then to be calculated as follows: 
PreO~PreP/(1-PreP) 
PostO~PreO*LRn 
[0051] Finally, post-test probability 120 may be deter-
mined according to the following formula: 
PostP~PostO/(PostO+ 1) 
[0052] The probability of death may be calculated using 
the instances of death within the matching reference patient 
data 72. For example, the present invention can report the 
percentage of matched patients tested for PE who survived 
for three or more months without sequelae. If a physician 
desires, he or she can use matching reference patient 72 to 
determine the probability of adverse outcomes that would 
mandate specific treatment had the outcome been foreseen at 
the time of patient presentation. For example, for a patient 
with anterior chest pain, the present invention can report the 
percentage of matched patients from a chest pain reference 
database that required acute percutaneous coronary revas-
cularization. The calculated probabilities for any or all of the 
these additional calculations 120, 140, 170 may be displayed 
190 and stored in memory 200 with time and date stamps for 
future uploading to a server or an associated network storage 
device. 
[0053] FIG. 3 depicts a clinical example of a linear 
comparison to a hypothetical reference database according 
to the method of the present invention for determining the 
probabilities associated with of a specific disease, PE. The 
patient in the example is a 57 year old white female with 
history of PE one year prior, presents with shortness of 
breath starting yesterday, nonproductive cough for one week 
and sudden onset pleuritic chest pain "exactly like" the 
previous PE last year. She smokes cigarettes and has been 
previously told she has the condition of fibromyalgia. She 
takes estrogen replacement therapy for hot flashes. Her vital 
signs are as follows: pulse 103, respiratory rate 28, sBP 141, 
Sa02 % 98%, and no leg swelling. 
[0054] FIG. 3 also depicts the process of matching six 
successive continuous parameters from an unknown patient 
to the database, age, pulse oximetry (Sa02 % ), heart rate 
(HR), respiratory rate (RR), systolic blood pressure (sBP), 
and temperature, (Temp). These parameters, their order, and 
the number and width of intervals for each parameter are 
shown for the purpose of describing the operation of the 
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present invention and do not necessarily represent the order 
or criteria that will be used in actual practice. 
[0055] As shown, the patient data is sorted and compared 
to the reference database, hypothetically containing 1,500 
previously studied patients. The example patient is matched 
to patients in the database who also fall within the prede-
termined ranges shown (a match is represented by the 
darkened ovals). In this example, the process of matching 
the patient's age and vital signs has narrowed the number of 
patients in the hypothetical database down to 105 patients 
who have recorded clinical data similar to that of the sample 
patient. 
[0056] The number of matches is further narrowed by 
matching considering the following data (with the hypo-
thetical patient data in parenthesis): dyspnea (yes), syncope 
(no), substemal chest pain (no), pleuritic chest pain (yes), 
non-productive cough (yes), hemoptysis (no), oral contra-
ceptives (no), prior PE or DVT (yes), active malignancy 
(no), recent Surgery (no), immobility (no), smoker (yes), 
asthma, COPD or other chronic lung disease (no), unilateral 
leg swelling (no), and wheezing (no). Consideration of these 
factors returns fifteen patients out of the 105 who had all of 
the cardinal parameters exactly the same as the patient's 
cardinal parameters. If one of the fifteen matches was 
ultimately diagnosed with PE, the example patient's pretest 
probability will be one-fifteenth or 6.7 percent, with a 95 
percent confidence interval of zero to 32 percent, using the 
aforementioned formulae. Consideration of conditional vari-
ables narrows the number matches even further, returning a 
smaller set of patients (e.g., perhaps five) who are even more 
similar to the example patient. 
[0057] The post-test probabilities of PE if the patient 
undergoes a CT scan of the chest, can be determined from 
the hypothetical results as follows. Assuming a likelihood 
ratio negative of 0.1 and likelihood ratio positive of 10, the 
post-test probability of PE after a negative CT scan would be 
0.75% and the post-test probability of PE if the CT scan is 
positive would be 43%. The present invention may provide 
this computation for all other diagnostic tests with published 
likelihoods that are pertinent to the evaluation of the disease 
in question. 
[0058] As seen in FIG. 4, the present system and method 
can also be used to perform attribute matching for assisting 
a physician in determining the degree of abnormality of a 
vital sign of a patient by evaluating a vital sign or signs 
against the vital sign of patients having similar attributes. 
Attribute matching provides a direct comparison of a patient 
of interest to those patients contained in a previously col-
lected database who share the same clinical profile of the 
patient of interest. For example, a 23-year old white female 
who weighs 95 pounds and is 5'2" tall, and has no disease 
co-morbidity, and no history of hypertension or hypotension, 
can be compared directly with patients of similar composi-
tion (e.g., white female age of greater than 18 but less than 
30 years, with body weight between 90 and 100 pounds, 
height between 5 feet and 5'5", and with no prior medical 
history). The system and method of the present invention 
will return only the females that match the attributes input 
into the profile, and their mean, standard deviation, range 
and other descriptive statistics of their systolic blood pres-
sure. The results of the attribute matching of the present 
invention may be exported to a electronic medical record 
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(EMR) system, printed onto hard copy for inclusion in the 
patient's chart, displayed in real time for evaluation by the 
physician or appropriate medical staff member, and/or stored 
in electronic format for future reference. 
[0059] Assuming the blood pressure was measured in a 
setting similar to that of the patient of interest (e.g., emer-
gency department, physician office, clinic or pharmacy), 
then the blood pressure of the patient of interest can be 
statistically compared to the results of the matched group. 
The elusive "standard in care" can thus help to be defined to 
determine whether the variable (in this case, systolic blood 
pressure) really was outside of expected ranges for a group 
of similar patients. This result would be useful in cases of 
risk management cases or medical malpractice cases. 
[0060] Those of ordinary skill in the art would recognize 
that the same methodology could be used to determine 
multiple other dichotomous or ordinal variables. For 
example, to determine whether or not it is appropriate to 
disregard a family history of cancer when evaluating a 
patient with a history of blood in his/her stool. Without 
comparing a patient of concern to a large reference patient 
population, it is difficult to know the real significance of a 
family history of cancer without direct comparison to like 
patients. It is possible for logistic regression and other 
statistical methods to produce a measure of strengths of 
association between the factor (in this case, family history) 
and the outcome of interest in the individual patient. 
[0061] Referring to FIG. 5, the method of determining the 
degree of abnormality of a vital sign of a patient begins by 
obtaining the clinical profile of the patient 210. The clinical 
profile should include at least one patient attribute 212, such 
as height, weight, etc., and at least one vital sign of interest 
214 whose degree of abnormality will be determined. The 
patient attribute(s) 212 are then compared 216 against 
previously evaluated patients whose clinical profiles have 
been stored in a database 218. Based on attribute matching 
of the patient attribute(s) 212 to the stored attributes 218, the 
clinical profiles of previously evaluated patients are 
retrieved 220. The statistical difference(s) are then calcu-
lated 222 based on a mathematical comparison between the 
patient's vital sign of interest 214 and the corresponding 
vital signs of the previously evaluated patients 218. The 
calculated statistical difference 222, as well as the patient 
attributes 212 and vital sign of interest 214 may then be 
exported to a electronic medical record (EMR) system 224, 
printed onto hard copy 226 for inclusion in the patient's 
chart, displayed in real time for evaluation by the physician 
or appropriate medical staff member 228, and/or stored in 
electronic format 230 for future reference. 
What is claimed is: 
1. The method of determining the degree of abnormality 
of at least one vital sign of a patient, comprising the steps of: 
obtaining a clinical profile of said patient, wherein said 
clinical profile includes at least one patent attribute and 
at least one patient vital sign; 
inputting said clinical profile into a data processing unit; 
comparing said clinical profile of said patient to a data-
base containing a plurality of stored clinical profiles of 
previously evaluated patients, wherein each clinical 
profile of each said previously evaluated patient 
includes at least one stored attribute corresponding to 
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said at least one patent attribute and at least one stored 
vital sign corresponding to said at least one patient vital 
sign; 
retrieving said clinical profiles of said previously evalu-
ated patients from said database based on whether said 
stored attributes substantially match said at least one 
patient attribute; 
calculating a statistical difference between said at least 
one patient vital sign and said stored vital signs of said 
previously evaluated patients. 
2. The method of claim 1, further comprising the step of 
displaying said statistical difference. 
3. The method of claim 1, further comprising the step of 
exporting said clinical profile of said patient and said 
statistical difference to an electronic medical record system. 
4. The method of claim 1, further comprising the step of 
storing said clinical profile of said patient and said statistical 
difference in a computer storage medium. 
5. The method of claim 1, further comprising the step of 
printing said clinical profile of said patient and said statis-
tical difference. 
6. A system for determining the degree of abnormality of 
at least one vital sign of a patient, comprising: 
a data processing unit programmed to accept the inputting 
of a clinical profile for said patient, wherein said 
clinical profile includes at least one patent attribute and 
at least one patient vital sign; 
a database containing a plurality of stored clinical profiles 
of previously evaluated patients in communication with 
said data processing unit, wherein each clinical profile 
of each said previously evaluated patient includes at 
least one stored attribute corresponding to said at least 
one patent attribute and at least one stored vital sign 
corresponding to said at least one patient vital sign; 
wherein said data processing unit is further programmed 
to compare said clinical profile of said patient to said 
plurality of stored clinical profiles of previously evalu-
ated patients and retrieve said clinical profiles of said 
previously evaluated patients from said database if said 
stored attributes substantially match said at least one 
patient attribute; and 
wherein said data processing unit is programmed to 
calculate a statistical difference between said at least 
one patient vital sign and said stored vital signs of said 
previously evaluated patients. 
7. The system of claim 6, further comprising a display in 
communication with said data processing unit for displaying 
said statistical difference. 
8. The system of claim 6, wherein said data processing 
unit further comprises an interface for communicating with 
an electronic medical record system. 
9. The system of claim 6, further comprising a non-
volatile storage medium in communication with said data 
processing unit for storing said clinical profile of said patient 
and said statistical difference. 
10. The system of claim 6, further comprising a printer in 
communication with said data processing unit for printing 
said clinical profile of said patient and said statistical dif-
ference. 
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